Search results

fluticasone/formoterol (flutiform k-haler)

Indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate: • For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short-acting β2 agonist. • For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist. • flutiform k-haler) is indicated in adults and adolescents aged 12 years and above.

fluticasone/formoterol (Flutiform)

For the licence extension of low strength flutiform (50/5 µg) in children aged 5 to <12 years. This fixed-dose combination of fluticasone propionate and formoterol fumarate (flutiform inhaler) is indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate: o For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short-acting β2 agonist. Or o For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist. flutiform 50 microgram/5 microgram inhaler is indicated in adults, adolescents and children aged 5 years and above.

fluticasone furoate (Avamys)

Allergic rhinitis in adults adolescents (12 years+) and children (6 to 11 years)

fluticasone/formoterol (Flutiform)

for the regular treatment of asthma where the use of a combination product [an inhaled corticosteroid (ICS) and a long-acting β2 agonist (LABA)] is appropriate: for patients not adequately controlled on ICS and ‘as required' inhaled short-acting β2 / for patients already adequately controlled on both an ICS and a LABA.

Fluticasone, salmeterol (Seretide Accuhaler®)

Severe chronic obstructive pulmonary disease

azelastine hydrochloride + fluticasone propionate (Dymista)

for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

fluticasone furoate / vilanterol (Relvar Ellipta®)

For the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate in patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists.

fluticasone furoate/vilanterol (Relvar Ellipta)

Symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.

fluticasone furoate / umeclidinium / vilanterol (Trelegy Ellipta)

Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.

salmeterol xinafoate fluticasone propionate combination inhaler (Seretide)

Symptomatic treatment of patients with chronic obstructive pulmonary disease (COPD)

salmeterol fluticasone 50/500 micrograms inhaler (Seretide 500 Accuhaler)

For the symptomatic treatment of patients with chronic obstructive pulmonary disease (COPD)

Seretide 50 Evohaler (Salmeterol xinafoate 25mcg/fluticasone propionate 50mcg)

Asthma